Zhang Xuelin, Xu Yunhua, He Chunya, Guo Xiaowei, Zhang Jian, He Chengzhi, Zhang Ling, Kong Min, Chen Baofu, Zhu Chengchu
Department of Thoracic Surgery, Taizhou Central Hospital, Taizhou, Zhejiang, China.
J Surg Oncol. 2015 Jun;111(7):834-9. doi: 10.1002/jso.23888.
CCAT2, a novel long non-coding RNAs (lncRNAs), is found to promote the metastasis and invasion of colon, lung, and breast cancers. This study aimed to investigate the level of CCAT2 in esophageal squamous cell carcinoma (ESCC) and to elucidate its clinical significance.
The expression level of CCAT2 and the status of MYC amplification were examined in 229 ESCC samples using quantitative real- time PCR.
CCAT2 was upregulated in ESCC tissues, especially in cases with lymph node metastasis (LNM), advanced TNM stages, and MYC amplification. Furthermore, the level of CCAT2 was positively correlated with TNM stages, LNM, and the number of positive lymph nodes. High CCAT2 expression and MYC amplification were significantly associated with TNM stages and LNM. Survival analyses revealed that high CCAT2 expression and MYC amplification were significantly associated with poorer overall survival in ESCC patients. Furthermore, patients with high CCAT2 expression and MYC amplification had a 2.199-fold increased risk of death compared with those with low CCAT2 expression and MYC non-amplification.
Our study provides the first evidence associating CCAT2 expression and poor survival in ESCC. CCAT2 may be a prognostic biomarker and therapeutic target for ESCC.
CCAT2是一种新型长链非编码RNA（lncRNA），已发现其可促进结肠癌、肺癌和乳腺癌的转移与侵袭。本研究旨在调查食管鳞状细胞癌（ESCC）中CCAT2的水平，并阐明其临床意义。
使用定量实时PCR检测229例ESCC样本中CCAT2的表达水平和MYC扩增状态。
CCAT2在ESCC组织中上调，尤其是在有淋巴结转移（LNM）、TNM分期较晚以及MYC扩增的病例中。此外，CCAT2水平与TNM分期、LNM以及阳性淋巴结数量呈正相关。CCAT2高表达和MYC扩增与TNM分期和LNM显著相关。生存分析显示，CCAT2高表达和MYC扩增与ESCC患者较差的总生存期显著相关。此外，与CCAT2低表达且MYC未扩增的患者相比，CCAT2高表达且MYC扩增的患者死亡风险增加了2.199倍。
我们的研究首次提供了ESCC中CCAT2表达与不良生存相关的证据。CCAT2可能是ESCC的一个预后生物标志物和治疗靶点。
